Close Menu
Home › Qiagen Syndromic Testing System, Respiratory Panel Garner FDA Clearance

Qiagen Syndromic Testing System, Respiratory Panel Garner FDA Clearance

May 20, 2019
|
staff reporter

NEW YORK (GenomeWeb) – Qiagen said today that its QiaStat-Dx syndromic testing system and multiplex respiratory pathogen panel have received 510(k) clearance from the US Food and Drug Administration.

With the clearance, Qiagen is commercially launching the products in the US, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
16
Featured Webinar

Using Next-Generation Sequencing to Detect Genomic Mutations in Hematologic Malignancies

Sponsored by
ArcherDX

This webinar will discuss a next-generation sequencing approach for detecting genomic mutations in hematologic maglignancies.

Oct
24
Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

What's Popular?

In PCR

  1. Quantabio Continues Newborn Screening Expansion as Tech Adopted by Wisconsin State Program

    Premium

  2. Genedrive Prepping for UK Commercial Launch of PGx Test for Neonatal Hearing Loss

    Premium

  3. OpGen Progresses on Pipeline of Highly Multiplexed Drug-Resistant Bacteria Tests

    Premium

  4. OpGen Stock Non-Compliant With Nasdaq Listing Requirement

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.